George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice coverage in last week's Independent: Http://www.independent.co.uk/news/business/sme/small-talk-labours-plan-to-cancel-the-cut-in-corporation-tax-has-the-virtue-of-fairness-10171795.html "Pioneering drug company boosted by marketing deal One Alternative Investment Market company hoping to buck the general malaise on the junior market is Akers Biosciences, which will today announce a deal to begin marketing one of its flagship treatments in Britain and eight other European countries. Akers, which has a dual Aim and Nasdaq listing, has developed a pioneering new test that can rapidly detect whether patients have a potentially fatal allergy to heparin, the blood thinning drug routinely used in hospitals around the world. The test is already in use in the US healthcare systems but Akers will now begin selling it far more widely across Europe, the Middle East and Africa. The potential for the test is enormous – while millions are prescribed heparin, as many as 5 per cent of them develop an allergy to the product. Patients undergoing serious heart surgery or major orthopaedic procedures are regarded as particularly vulnerable to such problems."
Dr. Akers to present on 23rd April at the Chesterfield Mayfair. Click here to register; http://tinyurl.com/ndxk35e
The infrastructure is certainly being put in place...once the sales follow through then the current tiny m/cap (almost wholly backed up by the cash pile anyway) will be extremely cheap imo: Http://www.investegate.co.uk/akers-biosciences--akr-/rns/distribution-agreements/201504130700139126J/ "Distribution Agreements Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, has added six new distributors to market its rapid tests for heparin‐induced thrombocytopenia ("HIT") in nine additional countries within Europe, the Middle East and Africa (EMEA). The Company has signed multi-year distribution agreements for PIFA Heparin/PF4 Rapid Assay products with Pathway Diagnostics Ltd, covering Great Britain; ACCUSCIENCE Ireland Ltd, covering Ireland and Northern Ireland; Tokra Medikal Tic Ltd Sti, covering Turkey; LabPro d.o.o, covering Serbia, Montenegro, Macedonia, Bosnia and Herzegovina; AVL Sofia Ltd, covering Bulgaria; and MASTERLAB SARL, covering Morocco. Akers has developed the only U.S. and E.U. cleared rapid test to detect a potentially fatal allergy to the widely used blood thinner, heparin. This clinical syndrome known as HIT reverses heparin's intended therapeutic effect and transforms it into a clotting agent. Patients suffering HIT are at risk of developing limb- and life-threatening complications, so the rapid diagnosis provided by the Company's Heparin/PF4 devices is paramount to effective, clinical decision making. Millions of patients are exposed to heparin around the world each year and between 1% and 5% of those patients receive a HIT diagnosis. The largest at-risk populations are patients undergoing major cardiac or orthopedic surgical procedures. "As sales of our rapid tests for HIT continue to rise in the U.S. we are actively seeking to roll out the marketing to other countries around the world," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board. "These additional distribution partnerships add to our expanding global footprint which now exposes the Company's flagship test to 20 non-U.S. markets including China," continued Dr. Akers. "Key to growing the international footprint is partnering with distributors with the right networks and experience to drive sales - in some cases in countries where there is no established procedure for testing for HIT," added Nicolas Daurel, Vice President, Sales and Marketing for EMEA. "We are confident that our international partners have these credentials and look forward to supporting their strategies.""
AKR still performing well and at around 310p in the USA, compared to 275p here. The CEO is presenting in London on 21st April...hopefully he'll have news flow to promote: Http://www.sharesoc.org/seminarapr2015.html
Up 13% in the USA to $4.86 on the open, or around 325p.
If AKR can sell into the US Government then other customers and markets will fall like dominoes: Http://www.investegate.co.uk/akers-biosciences--akr-/rns/distribution-agreement/201504020700132550J/ ADS Inc is "the world’s premier equipment, procurement, and support solutions specialist to the military, law enforcement, first responders, and the defense industry"..... Http://adsinc.com/
Presentation dated 18th March is here: Http://files.shareholder.com/downloads/AMDA-2AXZNZ/3753086041x0x726122/D0AABE71-A983-4C1A-81FE-2C31195877E1/AKERS_Company_Presentation.pdf Standouts for me are: - five products launched and commercialized, pipeline will result in eleven products in market by end of 2016 - Heparin test has potential to save a typical U.S. hospital well over $1m annually The results conference call is here, will try to listen soon: Http://ir.akersbiosciences.com/events.cfm
From Finncap this morning re the results - they also note the $9.7m of net cash: "Akers Biosciences*: Prelims (CORP) Revenues and EBITDA were in line with our estimates at US$4.4m (24% YoY growth) and US$-2.1m, respectively. Sales of the rapid test to detect a potentially fatal allergy to the blood thinner Heparin (PIFA Heparin/PF4) increased by 110% to $2.2m. With the global roll-out of PIFA Heparin/PF4 in China and Europe continuing, we anticipate further growth in 2015. We reiterate our 310p target price and make no changes to our forecasts."
Strong results show company growth and expansion. Revenue and GP increase and net assets higher - one for the future
Nice.... Http://www.investegate.co.uk/akers-biosciences--akr-/rns/european-patent-granted/201501260700090622D/ "European Patent Granted for Akers' Rapid Blood Separation Technology Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that the European Patent Office has issued a patent surrounding the Company's novel blood separator technology and method of separating a fluid fraction from whole blood (the "Technology"). Akers was granted U.S. patent protection for the Technology in 2011. The Technology, developed and wholly owned by Akers, enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. By utilizing the Technology, serum or plasma samples are extracted within 30-90 seconds and are ready for immediate analysis. By contrast, conventional methods of blood cell separation are labor-intensive and time consuming, taking 30-120 minutes, and typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialized equipment. The Technology, which further accelerates the rate at which a test result is obtained, is marketed by Akers under the brand name seraSTAT® and forms a key component of the Company's PIFA product range (Akers' proprietary platform for rapidly detecting or measuring specific proteins or other substances through their properties as antigens or antibodies). In addition to seraSTAT®'s incorporation within some of the Company's own diagnostic tests, Akers intends to license its proprietary blood separator Technology to third parties seeking to accelerate their own testing procedures by facilitating the blood cell separation process as a component of their test. "We believe the Company's blood separator Technology has a wide range of potential applications and we are actively seeking potential commercialization partners and licensees in both Europe and the U.S.," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board. "This Technology can make blood cell separation dramatically quicker and less resource-intensive than traditional methods - with significant potential advantages related to cost savings, staff efficiency, and the ability to perform certain diagnostic tests in the field versus lab environments," continued Dr. Akers."
Good to see the share price moving up again today - there doesn't seem to be much stock around given that a single buy caused a tick up, whilst a sell achieved a good premium to the bid price. If AKR achieve the numbers in this interview then the share price should move a long way forward from here, especially considering the current $10.2m cash pile against the £12.8m m/cap. "5 Jan 2015 "ORLANDO, Fla., Jan. 5, 2015 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. today announced that "The RedChip Money Report: Small Stocks Big Money"(TM) television program host Dave Gentry interviewed Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of Akers Biosciences (AKER). During the interview, Dr. Akers provides insight into the Company's current value, growth prospects, and overall opportunity. The interview is now available online at: hTTp://youtu.be/Mpl-mrERQ_0 Aegis Capital has an $11 per share price target on Akers Biosciences, which currently trades at 1.26x book value at $3.70 per share. During the interview, Dr. Akers reconfirms the Company's 2014 revenue guidance of $4 million to $5 million and forecasts 2015 revenues of $7.2 million to $10 million. Akers Biosciences is expected to reach profitability once it reaches $8.8 million in annual sales." hTTp://finance.yahoo.com/news/dave-gentry-interviews-akers-biosciences-152207801.html
3 Jan 2015 - do not think this means too much other than it is approved for such pruposes / by the Department of Health: Approved Prearrest and Evidential Breath Testing Devices CONFORMING PRODUCTS LIST OF ALCOHOL SCREENING DEVICES Akers Biosciences, Inc., Thorofare, New Jersey Breath Alcohol xx .02 Detection System.8 8 The Breath Alcohol xx .02 Detection System consists of a single-use disposable breath tube used in conjunction with an electronic analyzer that determines the test result. The electronic analyzer and the disposable breath tubes are lot specific and manufactured to remain calibrated throughout the shelf-life of the device. This screening device cannot be used after the expiration date. hTTp://www.pabulletin.com/secure/data/vol45/45-1/24.html "Prearrest breath testing devices approved under this authority may be used by police officers, waterways patrolmen and officers enforcing the Vehicle Code, the Fish and Boat Code and the Game and Wildlife Code in conducting preliminary determinations of the alcohol content of blood of persons suspected of driving, boating, hunting or furtaking while under the influence of alcohol. Officers and patrolmen use these devices to assist them in determining whether or not a person should be placed under arrest for violation of 75 Pa.C.S. § 3802 (relating to driving under influence of alcohol or controlled substance), for violation of 30 Pa.C.S. § 5502 (relating to operating watercraft under influence of alcohol or controlled substance), for violation of 34 Pa.C.S. § 2501 (relating to hunting or furtaking prohibited while under influence of alcohol or controlled substance) or for any other criminal offense under the Vehicle Code, the Fish and Boat Code or the Game and Wildlife Code which involves operating a vehicle or boat, hunting or furtaking while under the influence of alcohol."
2 Jan 2015 - Bright Outlook and New Products on the Way Prompt Analyst Report of Akers Bioscience Issued by BrokerBank Securities: hTTp://www.barchart.com/headlines/story/4718345/bright-outlook-and-new-products-on-the-way-prompt-analyst-report-of-akers-bioscience-issued-by-brokerbank-securities Revenue for 2015 is projected at $10.5m with a profit of $1m...... "Target price for AKER is estimated at $11.80. The target price is based on the current P/S multiple of 5.57x (ttm) and an estimated revenue of 10.5M or $2.12 per share. The target price is well above today’s trading price of $4.15 leading to a buy recommendation for Aker. Today’s price is considered an attractive entry point considering that AKER is trading just above the book value (1.26x), has no debt, has significant cash in their balance sheet and is generating revenue from its current product lines and has several new product lines launching in FY2015. Summary & Conclusion Aker Bioscience Inc. has much to smile about in the upcoming fiscal year. The PIFA Heparin PF4 Rapid Assay product line has been very successful in the US and has now been approved for distribution in Europe (press release Dec 18). With several more product lines nearing distribution stages, the outlook for FY 2015 is nothing but positive. Revenue is expected to double estimates of FY2014 and share price is estimated at $11.80."
...and up to $4 in the USA.
There can't be much stock around given this rise on small volumes. Hopefully the Daily Mail's readership will continue to buy for a while yet after that tip for 2015.
Good to see 2015 starting brightly. With AKR's $10.2M cash pile not too far off the entire £11M m/cap there's still plenty of upside here imho. Hopefully the NASDAQ price will continue to gain momentum, at least back to the $5.50 IPO price, which would equate to around 350p here in the UK.
It's also worth noting that the current price on the NASDAQ is $3.99, or around 254p - quite a lot higher than the current 227p UK price, so perhaps a buying opportunity for UK buyers: http://finance.yahoo.com/q?s=AKER&ql=0
The Daily Mail have tweaked their page of tips for 2015 and now include the narrative for AKR's tip as follows - note that the m/cap is only £11m, not the quoted £15m: Http://www.thisismoney.co.uk/money/investing/article-2890431/Shares-vote-2015-Daily-Mail-s-City-reporters-reveal-market-tips.html "Ian Lyall - Akers Bioscience If you look at the share price chart of Akers Bioscience you’d think it hadn’t been a particularly clever year for the diagnostics company. Yet in the past 12 months it has done everything it said it would. The company has developed a rapid test for an allergic reaction to the blood thinner heparin. In the developed Western medical system it offers a cheap and very timely alternative to the current lab tests. In developing economies such as China, where there currently are no lab tests, it will go on to be the gold standard diagnostic. Indeed the group received its first big order (for £640,000) from the People’s Republic. There is the promise of more of these deals next year as Akers continues to sign distribution agreements. Broker finnCap says the firm will break even in 2016; however at the current run rate the golden milestone could come much earlier. It has around £8million of cash in the bank – enough to last three years – and is valued at just £15.5million. The heparin test is the first of a number of potential big sellers rolling off the Akers production line, including rapid diagnostics for lung cancer and cholesterol."
Excellent news: http://www.thisismoney.co.uk/money/investing/article-2890431/Shares-vote-2015-Daily-Mail-s-City-reporters-reveal-market-tips.html#newcomment Shame the online version has somehow omitted the narrative....
Nice to see hints of breakeven this coming year, and good comments from Finncap at the end: Http://www.proactiveinvestors.co.uk/companies/news/75640/akers-biosciences-delivering-with-a-strong-end-to-the-year-75640.html "Akers Biosciences delivering with a strong end to the year By Ian Lyall December 19 2014, 3:41pm Akers’s product is the only US FDA-cleared rapid manual assay that is able to quickly determine if a patient being treated with the blood thinner heparin (pictured) may be developing a drug allergy. Akers Biosciences (LON:AKR, NASDAQ:AKER) is ending the year on a high note with every indication that the momentum will carry into 2015. Unveiling three deals little over a week apart, the company is delivering the planned roll-out strategy for its heparin allergy test, the flagship product in the portfolio. “Our plan was to first to grow the internal sales and marketing and come up with new, innovative strategies and go out and implement,” said chairman Ray Akers. “You need one or two things to break a log jam and then all hell breaks loose. That’s what is happening now.” On Thursday the group revealed it bagged two European distribution deals for its lead product, PIFA Heparin Rapid Assay. Its deal with Cryopep covers France, Belgium, the Netherlands and Luxembourg, while an agreement with DialLine covers Switzerland and Lichtenstein. Akers is confident of finding partners in other European territories, including the UK and Germany. However, the most important piece of news was the receipt last week of a US$1mln order for the heparin test from NovoTek, the Beijing‐based pharmaceutical and medical device business. “The Chinese market is as big as the US and there isn’t product approved there, so that is a market that’s going to rocket,” said chairman Akers. “We automatically become the gold standard. In Europe there are established laboratory methods and a much more entrenched medical system than there is in China, so the uptake in Europe won’t be as fast – but it will be steady.” Akers’s product is the only US FDA-cleared rapid manual assay that is able to quickly determine if a patient being treated with the blood thinner heparin may be developing a drug allergy. This clinical syndrome, known as heparin‐induced thrombocytopenia, or HIT for short, reverses the heparin’s intended effect and turns it into a clotting agent. Patients suffering HIT are at risk of developing limb and life-threatening complications, so fast and effective diagnosis of the problem is critical. It will be sold as a value proposition in established markets such as Europe, where it offers quicker diagnosis and crucially is cheaper than the established lab tests. Meanwhile, in emerging markets such as China, and India, where the firm also has a distribution deal, it is aiming to become the
Finncap reiterate their 310p target price after today's news (they also note in today's update the $10.2m net cash pile, which is not far off the entire £11m m/cap): Http://www.dakotafinancialnews.com/akers-biosciences-earns-corporate-rating-from-finncap-akr/3277/
Excellent news - AKR now have their first European international distribution agreements: Http://www.investegate.co.uk/akers-biosciences--akr-/rns/european-distribution-agreements/201412180700171204A/ France, Belgium, the Netherlands, Luxembourg, Switzerland and Lichtenstein are hopefully just the start. Looks like sizeable, respected partners too. The scale of the opportunity dwarfs the £10.7m m/cap since these add to "the already established distribution channels in the US, China, India, Australia and the Middle East".
Cheers for the link - it's good to hear: - the Novotek deal is a "gamechanger" - Novotek sales may be minimum $30m and perhaps even greater than Finncap's $67m - AKR's £10m cash pile should remain largely intact until cash break-even - the Chinese market is even greater than the US's $200m-$400m per annum All this for a company with a mere £10.9m m/cap almost entirely covered by its cash pile!
http://tinyurl.com/ku32ajz Ray Akers, the co-founder and executive chairman of Akers Biosciences (LON:AKR, NASDAQ:AKER), calls the US$1mln order from China for its Heparin allergy tests a ‘game changer’ for the group
Finncap retain their Buy and 310p valuation following yesterday's contract news - but in their note they also have this little gem. Not bad for a £11m m/cap company with cash almost equating to the m/cap: "Deal worth minima of US$67.2m. NovoTek is Akers' distribution partner for PIFA Heparin PF4 and PIFA PLUSS PF4 in China. The agreement is for nine years following regulatory approval and contains contractual minima: $1m per annum in years one to three, $4.8m in years four and five, $11.5m in years six and seven, rising to $15.8m in years eight and nine".